Prions food and drug safety /

Por Kitamoto, Tetsuyuki., International Symposium of Prion Diseases for Food and Drug Safety
Publicado em 2005

Pharmacokinetic drug interactions in liver disease: An update

Por Palatini, Pietro, De Martin, Sara
Publicado no World J Gastroenterol (2016)

Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development

Por Mittermayer, Friedrich, Caveney, Erica, Oliveira, Claudia De, Gourgiotis, Loukas, Puri, Mala, Tai, Li-Jung, J, Rick Turner
Publicado no Curr Diabetes Rev (2015)

Diabetes: glycaemic control in type 2 (drug treatments)

Por Gorter, Kees J, van de Laar, Floris Alexander, Janssen, Paul G H, Houweling, Sebastian T, Rutten, Guy E H M
Publicado em 2012

Development of a mobile application for vancomycin dosing calculation: A useful tool for the rational use of antimicrobials

Por Tácio de Mendonça Lima, Millena Padela da Silva, Luan Donato Silva Luz, Thais Cristina Amorim Estevão Soares, Etielle Silvestre Dantas, Gabriela Felix Teixeira, Rafael Henrique de Souza Costa, Sérgio Henrique Monte Santo Andrade
Publicado em 2022-03-01

Application of liposomes in drug development — focus on gastroenterological targets

Por Zhang, Jian-Xin, Wang, Kun, Mao, Zheng-Fa, Fan, Xin, Jiang, De-Li, Chen, Min, Cui, Lei, Sun, Kang, Dang, Sheng-Chun
Publicado em 2013

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Por Hunter Kerry, Hölscher Christian
Publicado em 2012-03-01

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions

Por Rosângela Teixeira, Yone de Almeida Nascimento, Déborah Crespo

Antiretroviral Treatment Failure, Drug Resistance, and Subtype Diversity in the Only Pediatric HIV Clinic in Rhode Island

Por Rogo, Tanya, DeLong, Allison K., Chan, Philip, Kantor, Rami
Publicado no Clin Infect Dis (2015)

Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery

Por Paola eImbrici, Antonella eLiantonio, Giulia Maria eCamerino, Michela eDe Bellis, Claudia eCamerino, Antonietta eMele, Arcangela eGiustino, Sabata ePierno, Annamaria eDe Luca, Domenico eTricarico, Jean-Francois eDesaphy, Diana eConte
Publicado em 2016-05-01

The Kidney in Type 2 Diabetes Therapy

Por Lambers Heerspink, Hiddo J., de Zeeuw, Dick
Publicado em 2011

Insulin and Autophagy in Neurodegeneration

Por Natália Prudente de Mello, Ana Maria Orellana, Caio Henrique Mazucanti, Geovanni de Morais Lima, Cristoforo Scavone, Elisa Mitiko Kawamoto
Publicado em 2019-05-01

Progressive cellular immune impairment leading to development of AIDS: two-year prospective study of HIV infection in drug addicts.

Por Fernandez-Cruz, E, Fernandez, A M, Gutierrez, C, Garcia-Montes, M, de la Morena, M T, Rodriguez-Villanueva, J, Longo, N, Zabay, J M
Publicado em 1988

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease

Por Federico, Alessandro, Zulli, Claudio, de Sio, Ilario, Del Prete, Anna, Dallio, Marcello, Masarone, Mario, Loguercio, Carmela
Publicado no World J Gastroenterol (2014)

IS6110 Restriction Fragment Length Polymorphism Typing of Drug-resistant Mycobacterium tuberculosis Strains from Northeast South Africa

Por Green, Ezekiel, Obi, Lawrence C., Okoh, Anthony I., Nchabeleng, Maphoshane, Villiers, Babsie E. De, Letsoalo, Tomas, Hoosen, Anwar A., Bessong, Pascal O., Ndip, Roland N.
Publicado em 2013

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

Por Johnson, Amy J., Lucas, David M., Muthusamy, Natarajan, Smith, Lisa L., Edwards, Ryan B., De Lay, Michael D., Croce, Carlo M., Grever, Michael R., Byrd, John C.
Publicado em 2006

The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes

Por Bacci, Marcelo Rodrigues, Cavallari, Marina Romera, de Rozier-Alves, Ross Martin, Alves, Beatriz da Costa Aguiar, Fonseca, Fernando Luiz Affonso
Publicado no Drug Des Devel Ther (2015)

Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity

Por de Boer, Richard, Smith, Ruben L., De Vos, Winnok H., Manders, Erik M. M., Brul, Stanley, van der Spek, Hans
Publicado no PLoS One (2015)

Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures

Por Sablón-Carrazana, Marquiza, Fernández, Isaac, Bencomo, Alberto, Lara-Martínez, Reyna, Rivera-Marrero, Suchitil, Domínguez, Guadalupe, Pérez-Perera, Rafaela, Jiménez-García, Luis Felipe, Altamirano-Bustamante, Nelly F., Diaz-Delgado, Massiel, Vedrenne, Fernand, Rivillas-Acevedo, Lina, Pasten-Hidalgo, Karina, Segura-Valdez, María de Lourdes, Islas-Andrade, Sergio, Garrido-Magaña, Eulalia, Perera-Pintado, Alejandro, Prats-Capote, Anaís, Rodríguez-Tanty, Chryslaine, Altamirano-Bustamante, Myriam M.
Publicado no PLoS One (2015)

Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008

Por de Valk, Harold W.
Publicado em 2008